Randy L Jensen1, Michael L Mumert, David L Gillespie, Anita Y Kinney, Matthias C Schabel, Karen L Salzman. 1. Corresponding author: Randy L. Jensen, MD, PhD, Huntsman Cancer Institute and Departments of Neurosurgery, Radiation Oncology, Oncological Sciences, Clinical Neuroscience Center, University of Utah, 175 North Medical Drive, Salt Lake City, Utah 84132. randy.jensen@hsc.utah.edu.
Abstract
BACKGROUND: Measures of tumor vascularity and hypoxia have been correlated with glioma grade and outcome. Dynamic contrast-enhanced (DCE) MRI can noninvasively map tumor blood flow, vascularity, and permeability. In this prospective observational cohort pilot study, preoperative imaging was correlated with molecular markers of hypoxia, vascularity, proliferation, and progression-free and overall patient survival. METHODS: Pharmacokinetic modeling methods were used to generate maps of tumor blood flow, extraction fraction, permeability-surface area product, transfer constant, washout rate, interstitial volume, blood volume, capillary transit time, and capillary heterogeneity from preoperative DCE-MRI data in human glioma patients. Tissue was obtained from areas of peritumoral edema, active tumor, hypoxic penumbra, and necrotic core and evaluated for vascularity, proliferation, and expression of hypoxia-regulated molecules. DCE-MRI parameter values were correlated with hypoxia-regulated protein expression at tissue sample sites. RESULTS: Patient survival correlated with DCE parameters in 2 cases: capillary heterogeneity in active tumor and interstitial volume in areas of peritumoral edema. Statistically significant correlations were observed between several DCE parameters and tissue markers. In addition, MIB-1 index was predictive of overall survival (P = .044) and correlated with vascular endothelial growth factor expression in hypoxic penumbra (r = 0.7933, P = .0071) and peritumoral edema (r = 0.4546). Increased microvessel density correlated with worse patient outcome (P = .026). CONCLUSIONS: Our findings suggest that DCE-MRI may facilitate noninvasive preoperative predictions of areas of tumor with increased hypoxia and proliferation. Both imaging and hypoxia biomarkers are predictive of patient outcome. This has the potential to allow unprecedented prognostic decisions and to guide therapies to specific tumor areas.
BACKGROUND: Measures of tumor vascularity and hypoxia have been correlated with glioma grade and outcome. Dynamic contrast-enhanced (DCE) MRI can noninvasively map tumor blood flow, vascularity, and permeability. In this prospective observational cohort pilot study, preoperative imaging was correlated with molecular markers of hypoxia, vascularity, proliferation, and progression-free and overall patient survival. METHODS: Pharmacokinetic modeling methods were used to generate maps of tumor blood flow, extraction fraction, permeability-surface area product, transfer constant, washout rate, interstitial volume, blood volume, capillary transit time, and capillary heterogeneity from preoperative DCE-MRI data in humangliomapatients. Tissue was obtained from areas of peritumoral edema, active tumor, hypoxic penumbra, and necrotic core and evaluated for vascularity, proliferation, and expression of hypoxia-regulated molecules. DCE-MRI parameter values were correlated with hypoxia-regulated protein expression at tissue sample sites. RESULTS:Patient survival correlated with DCE parameters in 2 cases: capillary heterogeneity in active tumor and interstitial volume in areas of peritumoral edema. Statistically significant correlations were observed between several DCE parameters and tissue markers. In addition, MIB-1 index was predictive of overall survival (P = .044) and correlated with vascular endothelial growth factor expression in hypoxic penumbra (r = 0.7933, P = .0071) and peritumoral edema (r = 0.4546). Increased microvessel density correlated with worse patient outcome (P = .026). CONCLUSIONS: Our findings suggest that DCE-MRI may facilitate noninvasive preoperative predictions of areas of tumor with increased hypoxia and proliferation. Both imaging and hypoxia biomarkers are predictive of patient outcome. This has the potential to allow unprecedented prognostic decisions and to guide therapies to specific tumor areas.
Authors: Nigel J P Beasley; Russell Leek; Mohammed Alam; Helen Turley; Graham J Cox; Kevin Gatter; Peter Millard; Sue Fuggle; Adrian L Harris Journal: Cancer Res Date: 2002-05-01 Impact factor: 12.701
Authors: Peter S LaViolette; Alex D Cohen; Melissa A Prah; Scott D Rand; Jennifer Connelly; Mark G Malkin; Wade M Mueller; Kathleen M Schmainda Journal: Neuro Oncol Date: 2013-02-03 Impact factor: 12.300
Authors: A Aria Tzika; Loukas G Astrakas; Maria K Zarifi; David Zurakowski; Tina Young Poussaint; Liliana Goumnerova; Nancy J Tarbell; Peter McL Black Journal: Cancer Date: 2004-03-15 Impact factor: 6.860
Authors: Andreas Stadlbauer; Kim Mouridsen; Arnd Doerfler; Mikkel Bo Hansen; Stefan Oberndorfer; Max Zimmermann; Michael Buchfelder; Gertraud Heinz; Karl Roessler Journal: J Cereb Blood Flow Metab Date: 2017-02-24 Impact factor: 6.200
Authors: I Hwang; S H Choi; C-K Park; T M Kim; S-H Park; J K Won; I H Kim; S-T Lee; R-E Yoo; K M Kang; T J Yun; J-H Kim; C-H Sohn Journal: AJNR Am J Neuroradiol Date: 2019-12-05 Impact factor: 3.825
Authors: Hee Soo Kim; Se Lee Kwon; Seung Hong Choi; Inpyeong Hwang; Tae Min Kim; Chul-Kee Park; Sung-Hye Park; Jae-Kyung Won; Il Han Kim; Soon Tae Lee Journal: Eur Radiol Date: 2020-01-17 Impact factor: 5.315